Navigation Links
Vasogen Provides Update on ACCLAIM II Program
Date:3/3/2008

tage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs.

Certain statements contained in this press release, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct addition
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014 Human ... and therapeutic company focused on extending the healthy, high ... Franz Och , Ph.D., an expert in machine ... Scientist. Och comes to HLI from Google where he ... Translate. He will report directly to HLI Co-Founder and ...
(Date:7/29/2014)... (July 29, 2014) Tough, ultralight foam of ... shape through a chemical process invented at Rice University. ... looks like a nanoscale building, with floors and walls ... pair of two-dimensional materials: floors and walls of graphene ... nitride platelets. , The researchers say the foam ...
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... 2014 Second generation biofuels are a viable ... fuels. However, as natural gas is very cheap, this is ... not as valuable as they could be in comparison to ... projects, has made it difficult for renewable energy developers to ... the ground. For these reasons, certain companies have shifted their ...
Breaking Biology Technology:Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2
... 5 Celator Pharmaceuticals today,announced that Andrew Janoff, ... the company,s business operations and clinical development,programs at ... Investor Conference on Tuesday, February 12, 2008 at ... About Celator, Celator Pharmaceuticals, Inc., is ...
... RICHMOND, Va., Feb. 5 Insmed Inc. (Nasdaq:,INSM) CEO ... House FY09 Budget and Food and Drug Administration statements ... is very pleased to see that the White House ... to,deliver safe and more affordable medicines to Americans., ...
... BioSeek, Inc. today,announced that Roy A. Whitfield has ... directors. Mr. Whitfield had joined BioSeek,s board of,directors ... Company since November,2005., "Roy,s management experience and ... extraordinarily valuable to BioSeek thus,far. We look forward ...
Cached Biology Technology:Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics 2BioSeek Elects Roy Whitfield Executive Chairman of Board of Directors 2
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... Essigmann and colleagues from the University of Washington had a ... could induce the virus to mutate uncontrollably, they could force ... that our immune system uses against many viruses. , ... mutate at an enhanced rate, as expected. But it did ... trial reported in 2011. In a new study, however, Essigmann ...
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... State University scientists and practitioners is riding herd on ... billion cattle industry: Bovine Respiratory Disease. BRD is ... United States, accounting for approximately 75 percent of feedlot ... feedlot deaths. BRD causes between $800 million to $900 ...
... (March 5, 2010) Research presented by P&G Beauty ... the American Academy of Dermatology (Miami Beach, FL, March ... insights into how ingredient formulations, care regimens and gene ... discussing a wide range of topics, including lipid metabolism ...
... (March 4, 2010) -- In a leap toward making stem ... Institute at Weill Cornell Medical College have discovered that endothelial ... produce growth factors that can grow copious amounts of adult ... Until now, adult stem cell cultures would die within four ...
Cached Biology News:Bovine respiratory disease 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 3P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 2Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 3Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 4Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 5Breakthrough reveals blood vessel cells are key to growing unlimited amounts of adult stem cells 6
... is ideal for the ... (1D electrophoresis, 2D electrophoresis, ... Pharmacokinetics & Toxicology (whole ... chromatography); Physical and Material ...
This kit is designed to select cells labeled with fluorescein isothiocyanate- (FITC-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Fujifilm BAS-1800II provides the ideal configuration for a low-cost imager that requires only a small amount of space in the laboratory. The small imager for accurate high-throughput screening...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
Biology Products: